Literature DB >> 2429797

Modulation of the immune response by immunoglobulin for intravenous use. II. Inhibitory effects of sera from treated patients.

W Stohl, C Cunningham-Rundles, C Thompson, L Mayer.   

Abstract

Sera were collected from patients with common varied immunodeficiency (CVI) prior to and following intravenous gamma-globulin (IVGG) infusion. Cultures of pokeweed mitogen (PWM)-stimulated peripheral blood mononuclear cells from normal donors in medium containing post-IVGG infusion sera generated significantly fewer plaque-forming cells (PFC) than those cultures in medium containing the corresponding pre-IVGG infusion sera. However, preinfusion CVI sera were found to be similar to normal sera in their capacities to support PWM-induced PFC generation, despite the disparity in Ig levels between the two groups of sera. Furthermore, serum collected from a CVI patient 24 hr or more after IVGG infusion no longer possessed the same inhibitory capacity as serum collected 10 min after IVGG infusion despite elevated IgG levels compared to baseline. These studies suggest that IVGG infusion may induce an immunosuppressive effect which is transient in nature, raising the possibility of in vivo counterbalancing homeostatic mechanisms responding to this immune perturbation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2429797     DOI: 10.1016/0090-1229(86)90111-x

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  3 in total

Review 1.  Immunomodulatory action of intravenous immunoglobulin.

Authors:  W A C Sewell; S Jolles
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

2.  Some characteristics of aggregates of IgG and plasma proteins in heat-treated factor VIII concentrates.

Authors:  C Wadsworth; L A Hanson; H Kjellman; T Söderström; M Blombäck
Journal:  Blut       Date:  1989-03

3.  Inhibition of T cell-dependent human B cell proliferation and B cell differentiation by polyspecific monomeric IgG.

Authors:  W Stohl; L Mayer
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.